About this trial
Demographic aging is predicted to be one of the most significant social changes of the 21st century. Aging is a slow, multifactorial process that progressively impacts the integrity of cells, tissues, and organs. This decline in function increases the risk of numerous diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases (CVD). CVD, the leading global cause of death, becomes more prevalent with age. Aging contributes to endothelial dysfunction, vessel stiffness, thickening, and impaired platelet function. These changes disrupt hemostatic processes and increase the risk of cardiovascular complications. Despite preventive strategies CVD remain a major public health challenge. Cellular aging, or senescence, affects all cell types, particularly endothelial cells and platelets. However, little research has compared the aging rates of different blood vessel types, such as arteries and veins. Given their distinct compositions and developmental origins, it is likely that their aging processes differ at molecular, cellular, and physiological levels.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Major patients requiring coronary artery bypass grafting (CABG).
Disqualifiers
Hypertension, diabetes, systemic inflammatory disease.
Trial population
Patients requiring coronary artery bypass grafting (CABG).
Trial design
Cohort
Prospective
Treatments tested in this trial
Graft collection
Procedure/SurgerySampling of superior venous and arterial grafts (internal mammary artery, great saphenous vein) after coronary artery bypass surgery.
Treatment groups
Trial outcomes
Primary outcomes
Biomarkers of ageing
Detection of innovative biomarkers of ageing by microscope analysis.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.